Clinical Trial Update: Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol L clinical trial evaluating MLN0128 (TAK-228) for cancers with mTOR genetic changes; status is ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma

Drugs mentioned

• MLN0128 (TAK-228) (MLN0128)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING